New hope for young bone cancer patients: adding a drug to standard chemo
NCT ID NCT07321912
Summary
This study is testing if adding a drug called eflornithine (DFMO) to standard chemotherapy helps young people with Ewing sarcoma or osteosarcoma. It aims to see if this combination helps patients live longer without their cancer coming back. The trial will enroll about 406 participants across different groups, including those with newly diagnosed or returning cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.